The European Medicines Agency (EMA) said on Monday it would no longer post on X and would use rival Bluesky instead, becoming ...

AMSTERDAM (Reuters) - The European Medicines Agency (EMA) said on Monday it would ... responsible for the scientific evaluation, supervision and safety monitoring of medicines.

AMSTERDAM (Reuters) - The European Medicines Agency (EMA) said on Monday it would no longer ... EMA is a decentralised agency of the EU, responsible for the scientific evaluation, supervision and ...

EMA is a decentralised agency of the European Union, responsible for the scientific evaluation, supervision and safety monitoring of medicines. Its headquarters is in Amsterdam, the Netherlands.

The government agency says X no longer suits its communication needs.

EMA validates X4 Pharma’s marketing authorization application for mavorixafor to treat WHIM syndrome: Boston Monday, January 27, 2025, 11:00 Hrs [IST] X4 Pharmaceuticals, a comp ...

Days after the European Commission (EC) granted approval, the UK’s Medicines and Healthcare Regulatory Agency (MHRA) has ...

X4 Pharmaceuticals (XFOR) announced that its Marketing Authorization Application for mavorixafor for the treatment of WHIM syndrome, a rare ...

In the United States, the biomedical industry encounters numerous regulatory challenges in conducting nonclinical and ...

Submission supported by positive results from global, Phase 3 4WHIM clinical trial;U.S. regulatory approval in WHIM syndrome granted in ...

Following the licensing agreement with X4 Pharmaceuticals, Norgine is pleased to see the announcement from X4 today that their Marketing Authorization Application (MAA) for ...

The FDA accepts and grants priority review to Merck's sNDA for Welireg to treat advanced pheochromocytoma and paraganglioma.